Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 568,785
  • Shares Outstanding, K 209,112
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • EBIT $ -285 M
  • EBITDA $ -278 M
  • 60-Month Beta 0.84
  • Price/Sales 5,624.01
  • Price/Cash Flow N/A
  • Price/Book 1.04

Options Overview Details

View History
  • Implied Volatility 131.59% ( +23.34%)
  • Historical Volatility 76.60%
  • IV Percentile 72%
  • IV Rank 18.30%
  • IV High 678.39% on 05/17/24
  • IV Low 9.15% on 08/15/24
  • Put/Call Vol Ratio 1.35
  • Today's Volume 80
  • Volume Avg (30-Day) 93
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 6,192
  • Open Int (30-Day) 5,995

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 12
  • High Estimate -0.30
  • Low Estimate -0.36
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +8.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.44 +22.95%
on 10/25/24
3.03 -0.83%
on 11/04/24
+0.30 (+11.11%)
since 10/04/24
3-Month
2.22 +35.14%
on 08/16/24
3.07 -2.12%
on 09/19/24
+0.43 (+16.73%)
since 08/02/24
52-Week
2.01 +49.25%
on 07/05/24
5.78 -48.05%
on 03/08/24
-0.50 (-14.29%)
since 11/03/23

Most Recent Stories

More News
Allogene Therapeutics Announces Participation in November Investor Conferences

ALLO : 3.00 (+10.29%)
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

ALLO : 3.00 (+10.29%)
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR Tâ„¢ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

ALLO : 3.00 (+10.29%)
Why is Wall Street So Bullish About These 2 Russell 2000 Stocks?

These smaller, rapidly expanding companies have significant growth potential.

ALLO : 3.00 (+10.29%)
$SPX : 5,712.69 (-0.28%)
IIPR : 130.63 (+2.86%)
GTBIF : 10.6800 (+3.79%)
CRLBF : 1.5300 (+0.99%)
TCNNF : 12.7000 (+3.44%)
Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics: Q2 Earnings Snapshot

ALLO : 3.00 (+10.29%)
Allogene Therapeutics: Q1 Earnings Snapshot

Allogene Therapeutics: Q1 Earnings Snapshot

ALLO : 3.00 (+10.29%)
Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 3.00 (+10.29%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 3.00 (+10.29%)
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Wall Street price targets suggest this stock can rocket more than 400% higher.

CRBU : 2.34 (+5.88%)
ALLO : 3.00 (+10.29%)
GILD : 89.84 (+0.37%)
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

/PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric...

ALLO : 3.00 (+10.29%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 3.50
2nd Resistance Point 3.26
1st Resistance Point 3.13
Last Price 3.00
1st Support Level 2.76
2nd Support Level 2.52
3rd Support Level 2.39

See More

52-Week High 5.78
Fibonacci 61.8% 4.34
Fibonacci 50% 3.89
Fibonacci 38.2% 3.45
Last Price 3.00
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar